Who are the top shareholders of the Aster DM Health.?

The top shareholders of Aster DM Health include promoters holding the majority, with Union Investments Private Limited owning 36.06%. Institutional investors, including mutual funds and foreign institutional investors, hold 23.46% and 23.62%, respectively, while individual shareholders collectively own 4.12%.

The top shareholders of Aster DM Health include a mix of promoters, institutional investors, and individual shareholders. The majority of the shares are held by promoters, with Union Investments Private Limited being the largest individual promoter, holding 36.06%. <BR><BR>In terms of institutional holdings, mutual funds account for 23.46% through 23 different schemes, while foreign institutional investors (FIIs) hold 23.62% of the shares. The highest public shareholder is Rimco (Mauritius) Limited, which owns 8.27%. Individual investors collectively hold 4.12% of the company’s shares. <BR><BR>Overall, the shareholding structure reflects a strong presence of promoter and institutional investors in Aster DM Health.

Who are in the management team of Aster DM Health.?

As of March 2022, the management team of Aster DM Health includes Chairman Mandayapurath Azad Moopen, Executive Director Alisha Moopen, and several non-executive and independent directors, totaling 12 members, including the Company Secretary. This diverse team oversees the company's governance and strategic direction.

As of March 2022, the management team of Aster DM Health includes the following individuals:<BR><BR>1. Mandayapurath Azad Moopen - Chairman & Executive Director<BR>2. Alisha Moopen - Executive Director / Deputy Managing Director<BR>3. Thadathil Wilson - Non Executive Director<BR>4. Anoop Moopen - Non Executive Director<BR>5. Shamsudheen Bin Mohideen Mammu Haji - Non Executive Director<BR>6. Daniel Robert Mintz - Non Executive Director<BR>7. C J George - Independent Non Executive Director<BR>8. James Mathew - Independent Non Executive Director<BR>9. Wayne Earl Keathley - Independent Non Executive Director<BR>10. Mr. Emmanuel David Gootam - Independent Non Executive Director<BR>11. DEEPTI PURANA HOUSDURGAMVIJAYA - Independent Non Executive Director<BR>12. Hemish Purushottam - Company Secretary & Compliance Officer<BR><BR>This team comprises a mix of executive, non-executive, and independent directors, contributing to the governance and strategic direction of the company.

When is the next results date for Aster DM Health.?

No Upcoming Board Meetings

Has Aster DM Health. declared dividend?

Aster DM Healthcare Ltd has declared a 40% dividend, amounting to ₹4 per share, with an ex-date of February 10, 2025. The company has demonstrated strong financial performance, achieving total returns of 577.43% over the past five years.

Aster DM Healthcare Ltd has declared a 40% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 40%<BR>- Amount per share: 4<BR>- Ex-date: 10 Feb 25<BR><BR>Dividend Yield: 1.03%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the company achieved a price return of 18.2%, a dividend return of 0.82%, resulting in a total return of 19.02%.<BR><BR>Over the past year, Aster DM Healthcare Ltd experienced a price return of 61.98%, a dividend return of 1.67%, leading to a total return of 63.65%.<BR><BR>In the 2-year period, the company saw a price return of 114.93%, a dividend return of 43.18%, culminating in a total return of 158.11%.<BR><BR>For the last 3 years, the price return was 207.85%, with a dividend return of 71.70%, resulting in a total return of 279.55%.<BR><BR>In the 4-year period, Aster DM Healthcare Ltd recorded a price return of 285.97%, a dividend return of 79.64%, achieving a total return of 365.61%.<BR><BR>Over the last 5 years, the company experienced a price return of 475.12%, a dividend return of 102.31%, resulting in a total return of 577.43%.<BR><BR>Overall, Aster DM Healthcare Ltd has not only declared a significant dividend but has also shown impressive total returns across multiple periods, indicating strong financial performance and shareholder value enhancement.

Who are the peers of the Aster DM Health.?

Aster DM Health's peers include Max Healthcare, Apollo Hospitals, Fortis Health, Narayana Hrudaya, Global Health, and others. Aster DM Health has average management risk, below average growth, and below average capital structure, with a 1-year return of 55.28%.

Peers: The peers of Aster DM Health are Max Healthcare, Apollo Hospitals, Fortis Health., Narayana Hrudaya, Global Health, Krishna Institu., Rainbow Child., Dr Agarwal's Hea, Jupiter Life Lin, and Health.Global.<BR><BR>Quality Snapshot: Excellent management risk is observed at Max Healthcare, Apollo Hospitals, Narayana Hrudaya, Global Health, Krishna Institu., Rainbow Child., Dr Agarwal's Hea, Jupiter Life Lin, and the rest. Average management risk is found at Fortis Health. and Aster DM Health., while below average management risk is noted at Health.Global. Excellent growth is seen at Max Healthcare and Apollo Hospitals, while good growth is observed at Fortis Health., Narayana Hrudaya, Dr Agarwal's Hea, and the rest. Below average growth is noted at Aster DM Health., Krishna Institu., Rainbow Child., and the rest. Excellent capital structure is seen at Max Healthcare, Global Health, Krishna Institu., and Jupiter Life Lin, while average capital structure is found at Apollo Hospitals and good capital structure at Fortis Health., Narayana Hrudaya, Dr Agarwal's Hea, Rainbow Child., and the rest. Below average capital structure is noted at Aster DM Health. and Health.Global.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Krishna Institu. at 85.63%, while the peer with the lowest is Dr Agarwal's Hea with no available data. Aster DM Health. has a 1-year return of 55.28%, which is lower than Krishna Institu. but higher than Dr Agarwal's Hea. Additionally, Rainbow Child. has a negative six-month return of -14.69%.

What does Aster DM Health. do?

Aster DM Healthcare Ltd is a prominent healthcare provider in the GCC and India, operating hospitals and classified as a large-cap company. As of March 2025, it reported net sales of ₹10,003 Cr and a net profit of ₹790 Cr, with a market cap of ₹31,072 Cr.

Overview:<BR>Aster DM Healthcare Ltd is a leading healthcare provider in the GCC and India, operating within the hospital industry and classified as a large-cap company.<BR><BR>History:<BR>Aster DM Healthcare Ltd was originally incorporated as 'Aster DM Healthcare Private Limited' on January 18, 2008, and was converted into a public limited company on November 29, 2013. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 10,003 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 790 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: INR 31,072 Cr (Large Cap)<BR><BR>Key Metrics:<BR>- P/E: 16.00<BR>- Industry P/E: 59<BR>- Dividend Yield: 0.98%<BR>- Debt-Equity: 0.19<BR>- Return on Equity: 58.18%<BR>- Price to Book: 9.06<BR><BR>Contact Details:<BR>Address: IX/475L Aster Medcity, Kuttisahib Road Cheranalloore Kochi Kerala : 682027<BR>Tel: 91-0484-6699228<BR>Email: investors@asterdmhealthcare.com<BR>Website: http://www.asterdmhealthcare.com

How big is Aster DM Health.?

As of 24th July, Aster DM Healthcare Ltd has a market capitalization of 31,276.00 Cr, with recent net sales of 4,138.46 Cr and a net profit of 5,377.83 Cr.

As of 24th July, Aster DM Healthcare Ltd has a market capitalization of 31,276.00 Cr and is classified as a Large Cap company.<BR><BR>In the latest four quarters, Aster DM Healthcare reported Net Sales of 4,138.46 Cr and a Net Profit of 5,377.83 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 4,559.79 Cr and Total Assets totaling 17,982.66 Cr.

Are Aster DM Health. latest results good or bad?

Aster DM Healthcare's latest Q2 FY26 results are strong, with a net profit of ₹110 crores and an 11.07% revenue increase quarter-on-quarter. However, concerns about long-term growth persist due to a five-year sales CAGR of -12.99%.

Aster DM Healthcare's latest results for Q2 FY26 indicate a strong performance overall. The company reported a net profit of ₹110.00 crores, which reflects a significant increase of 28.62% quarter-on-quarter. Revenue also saw healthy growth, reaching ₹1,197.21 crores, marking an 11.07% increase from the previous quarter and a 10.20% rise year-on-year.<BR><BR>The operating margin improved to 20.87%, up from 19.24% in the previous quarter, showcasing effective cost management and better operational leverage. Additionally, the profit after tax (PAT) margin increased to 10.13%, indicating that the improvements in operations are positively impacting the bottom line.<BR><BR>However, it's worth noting that while the recent quarter shows positive trends, the company's long-term growth profile has faced challenges, with a five-year sales CAGR of -12.99% and flat EBIT growth. This raises concerns about sustainability despite the current operational improvements.<BR><BR>In summary, Aster DM Healthcare's latest results are good in terms of quarterly performance, but the long-term growth trajectory remains a concern, which could affect investor sentiment moving forward.

Should I buy, sell or hold Aster DM Health.?

How has been the historical performance of Aster DM Health.?

Aster DM Health's historical performance shows strong growth in net sales and profitability metrics, with net sales rising from 2,994.05 Cr in Mar'23 to 4,138.46 Cr in Mar'25, while profit after tax increased from 170.81 Cr to 355.60 Cr. However, total operating income peaked in Mar'22 and has since declined, alongside a significant drop in total assets and liabilities.

Answer:<BR>The historical performance of Aster DM Health shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Aster DM Health's net sales have increased from 2,994.05 Cr in Mar'23 to 4,138.46 Cr in Mar'25, indicating a strong upward trend. However, total operating income peaked at 10,253.28 Cr in Mar'22 before declining to 4,138.46 Cr in Mar'25. The total expenditure, excluding depreciation, rose from 2,544.97 Cr in Mar'23 to 3,373.93 Cr in Mar'25, reflecting increased operational costs. Operating profit (PBDIT) also showed improvement, rising from 449.08 Cr in Mar'23 to 764.53 Cr in Mar'25, while profit before tax increased from 206.68 Cr in Mar'23 to 489.97 Cr in Mar'25. Profit after tax followed a similar trend, growing from 170.81 Cr in Mar'23 to 355.60 Cr in Mar'25. The earnings per share (EPS) surged dramatically from 8.51 in Mar'23 to 107.66 in Mar'25. On the balance sheet, total liabilities decreased significantly from 17,982.66 Cr in Mar'24 to 6,600.17 Cr in Mar'25, while total assets also declined from 17,982.66 Cr to 6,600.17 Cr in the same period. Cash flow from operating activities improved from 157.00 Cr in Mar'24 to 425.00 Cr in Mar'25, while cash flow from investing activities saw a substantial increase to -6,015.00 Cr in Mar'25. Overall, Aster DM Health has experienced a complex financial journey with notable improvements in profitability metrics despite fluctuations in total income and assets.

Is Aster DM Health. technically bullish or bearish?

As of November 19, 2025, Aster DM Health's trend is mildly bullish, supported by daily moving averages and KST indicators, despite some caution from the weekly MACD and recent price declines.

As of 19 November 2025, the technical trend for Aster DM Health has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by the daily moving averages indicating a positive trend. However, the weekly MACD is mildly bearish, which introduces some caution. The Bollinger Bands on both weekly and monthly time frames are mildly bullish, suggesting potential upward movement. The KST is bullish on both weekly and monthly charts, reinforcing the positive outlook. Despite recent price declines, the stock has shown strong returns over longer periods, outperforming the Sensex significantly in the 1Y, 3Y, and 5Y periods. Overall, while there are mixed signals, the prevailing trend remains mildly bullish.

Is Aster DM Health. overvalued or undervalued?

As of December 2, 2025, Aster DM Health is considered overvalued with a PE ratio of 92.00 and high valuation metrics compared to peers, despite a strong year-to-date return of 29.47%.

As of 2 December 2025, the valuation grade for Aster DM Health has moved from very expensive to expensive, indicating a slight improvement in perceived value but still reflecting high valuation metrics. The company is currently considered overvalued. Key ratios include a PE ratio of 92.00, an EV to EBITDA of 42.07, and a Price to Book Value of 7.60, all of which are significantly higher than industry norms.<BR><BR>In comparison to peers, Aster DM Health's PE ratio is notably higher than Apollo Hospitals at 62.27 and Narayana Hrudaya at 45.93, both of which are categorized as expensive. Additionally, Aster's PEG ratio stands at 0.00, suggesting no growth expectations priced into the stock, which is concerning. Despite a strong year-to-date return of 29.47% compared to the Sensex's 8.96%, the high valuation metrics indicate that Aster DM Health may not be a prudent investment at its current price of 665.10.

Which are the latest news on Aster DM Health.?

Why is Aster DM Health. falling/rising?

As of 03-Dec, Aster DM Healthcare Ltd's stock price is at 654.65, down 1.52%. The stock has shown short-term weakness with recent declines, but it has strong long-term performance, outperforming the BSE500 index year-to-date.

As of 03-Dec, Aster DM Healthcare Ltd's stock price is currently at 654.65, reflecting a decrease of 10.1 points or 1.52%. The stock has been experiencing a downward trend, having underperformed its sector by 0.62% today and has seen consecutive declines over the last two days, totaling a drop of 2.17%. Additionally, the stock reached an intraday low of Rs 648.9, which represents a decline of 2.38%.<BR><BR>Investor participation appears to be waning, as evidenced by a 9.03% decrease in delivery volume compared to the five-day average. While the stock remains above its 100-day and 200-day moving averages, it is below its 5-day, 20-day, and 50-day moving averages, indicating a short-term weakness in price momentum.<BR><BR>Despite these recent declines, it is important to note that Aster DM Healthcare has shown strong long-term performance, with a year-to-date return of 27.44% and a one-year return of 35.82%, significantly outperforming the BSE500 index over the same periods. However, the current negative price movement is primarily driven by short-term factors such as recent underperformance, declining investor participation, and the stock's position relative to its moving averages.